Merck & Co., Inc. (NYSE:MRK) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Merck & Co., Inc. (NYSE:MRK) had its price objective boosted by equities researchers at JPMorgan Chase & Co. from $150.00 to $165.00 in a report issued on Monday, Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 16.37% from the company’s previous close.

A number of other research analysts have also recently issued reports on the stock. Daiwa Securities Group raised shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price objective on the stock in a research note on Wednesday, August 12th. Berenberg Bank upped their target price on Merck & Co., Inc. from $127.00 to $137.00 and gave the stock a “hold” rating in a research note on Friday, September 11th. Royal Bank Of Canada downgraded Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and raised their target price for the company from $142.00 to $150.00 in a report on Thursday, August 20th. Jefferies Financial Group lifted their price target on Merck & Co., Inc. from $152.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Finally, Weiss Ratings raised Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 25th. Sixteen equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $146.36.

Merck & Co., Inc. Trading Up 1.6%

Shares of Merck & Co., Inc. stock opened at $141.78 on Monday. The company has a market capitalization of $349.81 billion, a price-to-earnings ratio of 113.43, a PEG ratio of 6.08 and a beta of 0.21. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a 12-month low of $82.01 and a 12-month high of $156.92. The firm’s 50-day moving average price is $143.10 and its two-hundred day moving average price is $127.76.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. During the same period in the previous year, the company earned $2.13 EPS. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, analysts forecast that Merck & Co., Inc. will post 2.76 earnings per share for the current fiscal year.

Insider Transactions at Merck & Co., Inc.

In other news, EVP Chirfi Guindo sold 10,000 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the transaction, the executive vice president directly owned 36,613 shares in the company, valued at approximately $4,942,755. This represents a 21.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP David R. Maraldo sold 18,706 shares of the stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the transaction, the executive vice president owned 18,212 shares of the company’s stock, valued at $2,344,248.64. The trade was a 50.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 228,238 shares of company stock valued at $29,977,783. Corporate insiders own 0.17% of the company’s stock.

Hedge Funds Weigh In On Merck & Co., Inc.

A number of institutional investors and hedge funds have recently bought and sold shares of MRK. Horizons Wealth Management acquired a new position in shares of Merck & Co., Inc. in the third quarter valued at approximately $30,000. Bullseye Investment Management LLC acquired a new stake in Merck & Co., Inc. during the 2nd quarter worth approximately $27,000. Abound Financial LLC acquired a new stake in Merck & Co., Inc. during the 4th quarter worth approximately $26,000. Graney & King LLC grew its holdings in Merck & Co., Inc. by 400.0% during the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after acquiring an additional 200 shares during the last quarter. Finally, Montgomery Financial Services LLC bought a new stake in Merck & Co., Inc. during the 2nd quarter worth approximately $41,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: JPMorgan raised its price target on Merck from $150 to $165 and reiterated an “overweight” rating. The new target implies meaningful upside and signals confidence in Merck’s earnings outlook. Merck Given New $165 Price Target at JPMorgan Chase
• Positive Sentiment: Analysts continue to view Merck’s recent monthly pullback as a potential entry point. Keytruda remains the company’s primary growth driver, while newer products and pipeline assets could help offset concerns about the drug’s post-2028 patent outlook. Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity?
• Positive Sentiment: Sell-side analysts collectively rate Merck “Moderate Buy,” providing additional support for the shares’ investment case. Merck Stock Rated Moderate Buy by Sell-Side Analysts
• Neutral Sentiment: Merck outperformed the broader market in the latest session, indicating that market momentum and investor interest also contributed to the stock’s move. Merck Beats Stock Market Upswing
• Negative Sentiment: Vaxcyte’s strong vaccine-candidate data drove a sharp rally in its shares and highlighted a potential competitor to Pfizer and Merck in the multibillion-dollar vaccine market. The development could increase competitive pressure on Merck’s vaccine business, although the commercial impact remains uncertain. Vaxcyte Vaccine Candidate Competition

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.